(Circulation. 2000;101:423.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Chronic NG-Nitro-L-Arginine Methyl Ester–Induced Hypertension
Novel Molecular Adaptation to Systolic Load in Absence of Hypertrophy
From the Charles A. Dana Research Institute and the Harvard-Thorndike Laboratory, Beth Israel Deaconess Medical Center, and Department of Medicine, Cardiovascular Division, Harvard Medical School, Boston, Mass.
Correspondence to Beverly H. Lorell, MD, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. E-mail blorell{at}caregroup.harvard.edu
Background—Chronic NG-nitro-L-arginine methyl ester (L-NAME), which inhibits nitric oxide synthesis, causes hypertension and would therefore be expected to induce robust cardiac hypertrophy. However, L-NAME has negative metabolic effects on protein synthesis that suppress the increase in left ventricular (LV) mass in response to sustained pressure overload. In the present study, we used L-NAME–induced hypertension to test the hypothesis that adaptation to pressure overload occurs even when hypertrophy is suppressed.
Methods and Results—Male rats received L-NAME (50 mg ·
kg-1 · d-1) or no drug for 6 weeks.
Rats with L-NAME–induced hypertension had levels of systolic
wall stress similar to those of rats with aortic stenosis
(85±19 versus 92±16 kdyne/cm). Rats with aortic stenosis
developed a nearly 2-fold increase in LV mass compared with controls.
In contrast, in the L-NAME rats, no increase in LV mass (1.00±0.03
versus 1.04±0.04 g) or hypertrophy of isolated myocytes
occurred (3586±129 versus 3756±135 µm2) compared
with controls. Nevertheless, chronic pressure overload was not
accompanied by the development of heart failure. LV systolic
performance was maintained by mechanisms of concentric
remodeling (decrease of in vivo LV chamber dimension relative to wall
thickness) and augmented myocardial calcium–dependent contractile
reserve associated with preserved expression of 
- and ß-myosin
heavy chain isoforms and sarcoplasmic reticulum Ca2+
ATPase (SERCA-2).
Conclusions—When the expected compensatory hypertrophic response is suppressed during L-NAME–induced hypertension, severe chronic pressure overload is associated with a successful adaptation to maintain systolic performance; this adaptation depends on both LV remodeling and enhanced contractility in response to calcium.
Key Words: nitric oxide • calcium • NG-nitroarginine methyl ester • hypertrophy • remodeling
This article has been cited by other articles:
 |
|
 |
|
  G. W. Booz Impact of T Lymphocytes on Cardiac Remodeling in Hypertension: More Questions Than Answers Hypertension, July 1, 2006; 48(1): 31 - 32. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, D. Bell, L. R. Smith, L. Zhao, A. B. Devine, E. M. McHenry, D. P. Nicholls, and B. J. McDermott Differential Expression of Components of the Cardiomyocyte Adrenomedullin/Intermedin Receptor System following Blood Pressure Reduction in Nitric Oxide-Deficient Hypertension J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1269 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bell, Y.-Y. Zhao, E. J. Kelso, E. M. McHenry, L. M. Rush, V. M. Lamont, D. P. Nicholls, and B. J. McDermott Upregulation of adrenomedullin and its receptor components during cardiomyocyte hypertrophy induced by chronic inhibition of nitric oxide synthesis in rats Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H904 - H914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kupari, H. Turto, and J. Lommi Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur. Heart J., September 1, 2005; 26(17): 1790 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Shah Divergent roles of endothelial nitric oxide synthase in cardiac hypertrophy and chamber dilatation? Cardiovasc Res, June 1, 2005; 66(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Booz Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System Hypertension, March 1, 2005; 45(3): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bourraindeloup, C. Adamy, G. Candiani, M. Cailleret, M.-C. Bourin, T. Badoual, J. B. Su, S. Adubeiro, F. Roudot-Thoraval, J.-L. Dubois-Rande, et al. N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-{alpha} Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats Circulation, October 5, 2004; 110(14): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fiedler and K. C Wollert Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 450 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Akazawa and I. Komuro Roles of Cardiac Transcription Factors in Cardiac Hypertrophy Circ. Res., May 30, 2003; 92(10): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Scopacasa, V. P. A. Teixeira, and K. G. Franchini Colchicine attenuates left ventricular hypertrophy but preserves cardiac function of aortic-constricted rats J Appl Physiol, April 1, 2003; 94(4): 1627 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. F. Bronzwaer, C. Heymes, C. A. Visser, and W. J. Paulus Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H10 - H16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, D. Carreras, and A. J. de Bold Discoordinate re-expression of cardiac fetal genes in N{omega}-nitro-L-arginine methyl ester (L-NAME) hypertension Cardiovasc Res, January 1, 2003; 57(1): 158 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nahrendorf, K. Hu, K.-H. Hiller, P. Galuppo, D. Fraccarollo, G. Schweizer, A. Haase, G. Ertl, W. R. Bauer, and J. Bauersachs Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1695 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Sampaio, J. E. Tanus-Santos, S. E. S. F. C. Melo, S. Hyslop, K. G. Franchini, I. M. Luca, and H. Moreno Jr Hypertension Plus Diabetes Mimics the Cardiomyopathy Induced by Nitric Oxide Inhibition in Rats Chest, October 1, 2002; 122(4): 1412 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M.A.C. Martens, B. Demeilliers, D. Girardot, C. Daigle, H. H. Dao, D. deBlois, and P. Moreau Vessel-Specific Stimulation of Protein Synthesis by Nitric Oxide Synthase Inhibition: Role of Extracellular Signal-Regulated Kinases 1/2 Hypertension, January 1, 2002; 39(1): 16 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichihara, T. Senbonmatsu, E. Price Jr, T. Ichiki, F. A. Gaffney, and T. Inagami Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II-Induced Hypertension Circulation, July 17, 2001; 104(3): 346 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Lorell and B. A. Carabello Left Ventricular Hypertrophy : Pathogenesis, Detection, and Prognosis Circulation, July 25, 2000; 102(4): 470 - 479. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hill, M. Karimi, W. Kutschke, R. L. Davisson, K. Zimmerman, Z. Wang, R. E. Kerber, and R. M. Weiss Cardiac Hypertrophy Is Not a Required Compensatory Response to Short-Term Pressure Overload Circulation, June 20, 2000; 101(24): 2863 - 2869. [Abstract] [Full Text] [PDF]
|
|